Lee P. Richman

2.3k total citations
25 papers, 931 citations indexed

About

Lee P. Richman is a scholar working on Immunology, Hematology and Oncology. According to data from OpenAlex, Lee P. Richman has authored 25 papers receiving a total of 931 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Immunology, 11 papers in Hematology and 8 papers in Oncology. Recurrent topics in Lee P. Richman's work include Immunotherapy and Immune Responses (11 papers), Hematopoietic Stem Cell Transplantation (11 papers) and T-cell and B-cell Immunology (7 papers). Lee P. Richman is often cited by papers focused on Immunotherapy and Immune Responses (11 papers), Hematopoietic Stem Cell Transplantation (11 papers) and T-cell and B-cell Immunology (7 papers). Lee P. Richman collaborates with scholars based in United States, Slovakia and United Kingdom. Lee P. Richman's co-authors include Robert H. Vonderheide, Andrew J. Rech, Ran Reshef, Dominic Poulin, Graeme Moyle, Grushenka H.I. Wolfgang, Hong Feng, Scott L. Friedman, Taishi Hashiguchi and Hiroyuki Yoneyama and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Lee P. Richman

25 papers receiving 909 citations

Peers

Lee P. Richman

IMMUN

ONCOL

EPIDE

HEPAT

Steven D. Hughes United States

Melissa M. Johnson United States

Lei Deng China

Keiko Koga Japan

P. Varlet France

Carlo Zibera Italy

Rita Ruijter Netherlands

Yinchen Dong United States

Eugene S. Medlock United States

Gillian McNab United Kingdom

Steven D. Hughes United States

Lee P. Richman

425 ×0.9

IMMUN

341 ×0.9

ONCOL

310 ×1.3

161 ×0.7

EPIDE

162 ×1.2

HEPAT

Citations per year, relative to Lee P. Richman Lee P. Richman (= 1×) peers Steven D. Hughes

Countries citing papers authored by Lee P. Richman

Since Specialization

Citations

This map shows the geographic impact of Lee P. Richman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lee P. Richman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lee P. Richman more than expected).

Fields of papers citing papers by Lee P. Richman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lee P. Richman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lee P. Richman. The network helps show where Lee P. Richman may publish in the future.

Co-authorship network of co-authors of Lee P. Richman

This figure shows the co-authorship network connecting the top 25 collaborators of Lee P. Richman. A scholar is included among the top collaborators of Lee P. Richman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lee P. Richman. Lee P. Richman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Richman, Lee P., Yogesh Goyal, Connie Jiang, & Arjun Raj. (2023). ClonoCluster: A method for using clonal origin to inform transcriptome clustering. Cell Genomics. 3(2). 100247–100247. 9 indexed citations

Bear, Adham S., Tatiana Blanchard, Michael Ford, et al.. (2021). Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. Nature Communications. 12(1). 4365–4365. 73 indexed citations

Pasin, Chloé, Alex Ganetsky, Lee P. Richman, et al.. (2021). Vitamin D deficiency after allogeneic hematopoietic cell transplantation promotes T-cell activation and is inversely associated with an EZH2-ID3 signature. Transplantation and Cellular Therapy. 28(1). 18.e1–18.e10. 3 indexed citations

Markosyan, Nune, Jinyang Li, Yu Sun, et al.. (2019). Tumor cell–intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2). Journal of Clinical Investigation. 129(9). 3594–3609. 114 indexed citations

Richman, Lee P., Robert H. Vonderheide, & Andrew J. Rech. (2019). Neoantigen Dissimilarity to the Self-Proteome Predicts Immunogenicity and Response to Immune Checkpoint Blockade. Cell Systems. 9(4). 375–382.e4. 92 indexed citations

Bear, Adham S., Andrew J. Rech, Lee P. Richman, et al.. (2019). Abstract B04: Identification of T-cell receptors targeting mutant KRAS in pancreatic cancer. Cancer Research. 79(24_Supplement). B04–B04. 1 indexed citations

Huffman, Austin P., Lee P. Richman, Alex Ganetsky, et al.. (2017). Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis. Biology of Blood and Marrow Transplantation. 24(3). 594–599. 5 indexed citations

Moy, Ryan H., Austin P. Huffman, Lee P. Richman, et al.. (2017). Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis. Blood. 129(7). 906–916. 43 indexed citations

Lefebvre, Éric, Graeme Moyle, Ran Reshef, et al.. (2016). Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PLoS ONE. 11(6). e0158156–e0158156. 256 indexed citations

10.

Moy, Ryan H., Austin P. Huffman, Lee P. Richman, et al.. (2015). Immunologic Effects of CCR5 Blockade in Graft-Versus-Host Disease Prophylaxis. Blood. 126(23). 920–920. 1 indexed citations

11.

Reshef, Ran, Austin P. Huffman, Marlise R. Luskin, et al.. (2015). A Survival Benefit for Reduced Intensity Allogeneic Transplants from Young Unrelated Donors Compared to Older Sibling Donors Depends on the Graft CD8 T-Cell Content. Biology of Blood and Marrow Transplantation. 21(2). S42–S43. 1 indexed citations

12.

Karimi, Mobin, Jerrod L. Bryson, Lee P. Richman, et al.. (2015). NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT. Blood. 125(23). 3655–3663. 33 indexed citations

13.

Chu, Niansheng, et al.. (2015). Toll‐like receptor 9 and interferon‐γ receptor signaling suppress the B‐cell fate of uncommitted progenitors in mice. European Journal of Immunology. 45(5). 1313–1325. 12 indexed citations

14.

Ganetsky, Alex, Lee P. Richman, Noelle V. Frey, et al.. (2014). Vitamin D Deficiency Predicts Acute Cutaneous Graft-Versus-Host Disease in Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 20(2). S267–S268. 7 indexed citations

15.

Reshef, Ran, Austin P. Huffman, Marlise R. Luskin, et al.. (2014). CD8 Cell Dose in Peripheral Blood Stem-Cell Grafts Correlates with Relapse and Survival after Reduced Intensity Allogeneic Stem-Cell Transplantation. Blood. 124(21). 1260–1260. 1 indexed citations

16.

Richman, Lee P. & Robert H. Vonderheide. (2014). Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking. OncoImmunology. 3(5). e28610–e28610. 9 indexed citations

17.

Bajor, David L., Xiaowei Xu, Drew A. Torigian, et al.. (2014). Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma. Cancer Immunology Research. 2(11). 1051–1058. 36 indexed citations

18.

Reshef, Ran, James K. Mangan, Selina M. Luger, et al.. (2014). Extended CCR5 Blockade in Graft-Versus-Host Disease Prophylaxis – a Phase II Study. Blood. 124(21). 2491–2491. 4 indexed citations

19.

Richman, Lee P. & Robert H. Vonderheide. (2013). Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer. Cancer Immunology Research. 2(1). 19–26. 72 indexed citations

20.

Huang, Jun, Hai‐Jing Zhong, Shannon Breen, et al.. (2012). 42 MEDI5117 Administration Confers Specific Inhibitions of IL-6 Related Growth Pathways in Tumor Xenograft Models. European Journal of Cancer. 48. 15–15. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact